Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Female sexual dysfunction (FSD) is an established side effect of Selective serotonin reuptake
inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs), causing symptoms
such as loss of libido, arousal difficulties, or delayed orgasm or anorgasmia.
Efficacy of testosterone therapy for the treatment of hypoactive sexual desire disorder
(HSDD) in women has been demonstrated in studies including naturally and surgically
menopausal women, either alone or in combination with estrogen, with or without progestin
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University Potiguar
Collaborators:
Federal Institute of Science and Technology of Ceara Universidade Federal do Ceara